{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T15:11:01Z","timestamp":1793373061400,"version":"4.5.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T00:00:00Z","timestamp":1635984000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T00:00:00Z","timestamp":1635984000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s10637-021-01178-3","type":"journal-article","created":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T11:37:37Z","timestamp":1636025857000},"page":"314-321","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["A phase 1 study of pegylated recombinant arginase\u00a0(PEG-BCT-100) in combination with systemic chemotherapy (capecitabine and oxaliplatin)[PACOX] in advanced hepatocellular carcinoma patients"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7114-0305","authenticated-orcid":false,"given":"Thomas","family":"Yau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul N. M.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerry Gin Wai","family":"Kwok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela M.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tan To","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi Tao","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,4]]},"reference":[{"key":"1178_CR1","doi-asserted-by":"publisher","first-page":"3501","DOI":"10.1200\/JCO.2012.44.5643","volume":"31","author":"S Qin","year":"2013","unstructured":"Qin S, Bai Y, Lim HY, Thongprasert S, Chao Y, Fan J et al (2013) Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil\/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J Clin Oncol 31:3501\u20133508","journal-title":"J Clin Oncol"},{"key":"1178_CR2","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J-F et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378\u2013390","journal-title":"N Engl J Med"},{"key":"1178_CR3","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","volume":"10","author":"A-L Cheng","year":"2009","unstructured":"Cheng A-L, Kang Y-K, Chen Z, Tsao C-J, Qin S, Kim JS et al (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25\u201334","journal-title":"Lancet Oncol"},{"key":"1178_CR4","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s00535-019-01642-1","volume":"55","author":"T Yamashita","year":"2020","unstructured":"Yamashita T, Kudo M, Ikeda K, Izumi N, Tateishi R, Ikeda M et al (2020) REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset. J Gastroenterol 55:113\u2013122","journal-title":"J Gastroenterol"},{"key":"1178_CR5","first-page":"267","volume":"39","author":"RS Finn","year":"2021","unstructured":"Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim T-Y et al (2021) IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC). JCO Wolters Kluwer 39:267\u2013267","journal-title":"JCO Wolters Kluwer"},{"key":"1178_CR6","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1054\/bjoc.2000.1353","volume":"83","author":"L Scott","year":"2000","unstructured":"Scott L, Lamb J, Smith S, Wheatley DN (2000) Single amino acid (arginine) deprivation: rapid and selective death of cultured transformed and malignant cells. Br J Cancer 83:800\u2013810","journal-title":"Br J Cancer"},{"key":"1178_CR7","doi-asserted-by":"publisher","unstructured":"Chan SL, Cheng PNM, Liu AM, Chan LL, Li L, Chu CM et al (2021) A phase II clinical study on the efficacy and predictive biomarker of pegylated recombinant arginase on hepatocellular carcinoma. Invest New Drugs [Internet]. 2021 [cited 2021 Jun 8]; Available from: https:\/\/link.springer.com\/https:\/\/doi.org\/10.1007\/s10637-021-01111-8","DOI":"10.1007\/s10637-021-01111-8"},{"key":"1178_CR8","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/sj.bjc.6605856","volume":"103","author":"T-S Yang","year":"2010","unstructured":"Yang T-S, Lu S-N, Chao Y, Sheen I-S, Lin C-C, Wang T-E et al (2010) A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients. Br J Cancer 103:954\u2013960","journal-title":"Br J Cancer"},{"key":"1178_CR9","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1093\/annonc\/mdy101","volume":"29","author":"GK Abou-Alfa","year":"2018","unstructured":"Abou-Alfa GK, Qin S, Ryoo B-Y, Lu S-N, Yen C-J, Feng Y-H et al (2018) Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma. Ann Oncol 29:1402\u20131408","journal-title":"Ann Oncol"},{"key":"1178_CR10","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s10637-012-9807-9","volume":"31","author":"T Yau","year":"2013","unstructured":"Yau T, Cheng PN, Chan P, Chan W, Chen L, Yuen J et al (2013) A phase 1 dose-escalating study of pegylated recombinant human arginase 1 (Peg-rhArg1) in patients with advanced hepatocellular carcinoma. Invest New Drugs 31:99\u2013107","journal-title":"Invest New Drugs"},{"key":"1178_CR11","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1007\/s10637-014-0200-8","volume":"33","author":"T Yau","year":"2015","unstructured":"Yau T, Cheng PN, Chan P, Chen L, Yuen J, Pang R et al (2015) Preliminary efficacy, safety, pharmacokinetics, pharmacodynamics and quality of life study of pegylated recombinant human arginase 1 in patients with advanced hepatocellular carcinoma. Invest New Drugs 33:496\u2013504","journal-title":"Invest New Drugs"},{"key":"1178_CR12","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13045-018-0612-6","volume":"11","author":"C De Santo","year":"2018","unstructured":"De Santo C, Cheng P, Beggs A, Egan S, Bessudo A, Mussai F (2018) Metabolic therapy with PEG-arginase induces a sustained complete remission in immunotherapy-resistant melanoma. J Hematol Oncol 11:68","journal-title":"J Hematol Oncol"},{"key":"1178_CR13","doi-asserted-by":"crossref","unstructured":"Cheng PN-M, Lam T-L, Lam W-M, Tsui S-M, Cheng AW-M, Lo W-H et al (2007) Pegylated recombinant human arginase (rhArg-peg5,000mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through arginine depletion. Cancer Res\u00a067:309\u201317","DOI":"10.1158\/0008-5472.CAN-06-1945"},{"key":"1178_CR14","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1001\/jamaoncol.2016.3049","volume":"3","author":"PW Szlosarek","year":"2017","unstructured":"Szlosarek PW, Steele JP, Nolan L, Gilligan D, Taylor P, Spicer J et al (2017) Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1-Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial. JAMA Oncol 3:58\u201366","journal-title":"JAMA Oncol"},{"key":"1178_CR15","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1200\/JCO.2016.71.3230","volume":"35","author":"E Beddowes","year":"2017","unstructured":"Beddowes E, Spicer J, Chan PY, Khadeir R, Corbacho JG, Repana D et al (2017) Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1-Deficient Thoracic Cancers. J Clin Oncol 35:1778\u20131785","journal-title":"J Clin Oncol"},{"key":"1178_CR16","doi-asserted-by":"publisher","first-page":"2708","DOI":"10.1158\/1078-0432.CCR-18-3729","volume":"25","author":"PE Hall","year":"2019","unstructured":"Hall PE, Lewis R, Syed N, Shaffer R, Evanson J, Ellis S et al (2019) A Phase I Study of Pegylated Arginine Deiminase (Pegargiminase), Cisplatin, and Pemetrexed in Argininosuccinate Synthetase 1-Deficient Recurrent High-grade Glioma. Clin Cancer Res 25:2708\u20132716","journal-title":"Clin Cancer Res"},{"key":"1178_CR17","doi-asserted-by":"crossref","unstructured":"Yau T, Kang Y-K, Kim T-Y, El-Khoueiry AB, Santoro A, Sangro B et al (2020) Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial. JAMA Oncol","DOI":"10.1001\/jamaoncol.2020.4564"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-021-01178-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-021-01178-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-021-01178-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T04:41:25Z","timestamp":1678509685000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-021-01178-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,4]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["1178"],"URL":"https:\/\/doi.org\/10.1007\/s10637-021-01178-3","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,4]]},"assertion":[{"value":"14 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approval was obtained from the ethics committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors of the study gave consent to publication of this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publication"}},{"value":"PC and AL are employees of Bio-Cancer Treatment International Ltd.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}